Pranidipine: Difference between revisions
CSV import |
CSV import |
||
| Line 23: | Line 23: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Revision as of 05:06, 11 February 2025
Pranidipine is a calcium channel blocker that is used primarily in the treatment of hypertension. It is a third-generation calcium channel blocker, developed in Japan and sold under the brand name Acalas.
Mechanism of Action
Pranidipine works by inhibiting the influx of calcium ions into cardiac muscle and smooth muscle cells. This inhibition leads to a decrease in muscle contraction, which in turn reduces the resistance in blood vessels and lowers blood pressure.
Pharmacokinetics
After oral administration, pranidipine is rapidly absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, resulting in a low bioavailability. The drug is primarily excreted in the urine.
Side Effects
Common side effects of pranidipine include headache, flushing, and dizziness. Less common side effects may include palpitations, abdominal pain, and rash.
Contraindications
Pranidipine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It is also contraindicated in patients with severe cardiac insufficiency.
Interactions
Pranidipine may interact with other drugs, including other calcium channel blockers, beta blockers, and ACE inhibitors. These interactions can lead to an increased risk of side effects or a decrease in the effectiveness of the drug.
References
<references />


